Purpose: F-FDG PET has been used for vascular disease, but its role in deep vein thrombosis (DVT) remains prospectively unexplored.

Patients And Methods: Whole-body F-FDG PET/CT scans were performed in patients 1 to 10 weeks after onset of symptomatic DVT (n = 12) and in control subjects without DVT (n = 24). The metabolic activity (SUVmax) of thrombosed and contralateral nonthrombosed vein segments was determined. The sensitivity and specificity of F-FDG PET/CT for the diagnosis of DVT were determined by receiver operating characteristic curve analyses. In 2 patients with DVT, changes in the metabolic activity of thrombosed vein segments in serial F-FDG PET scans.

Results: The metabolic activity in thrombosed veins [SUVmax, 2.41 (0.75)] was visually appreciable and significantly higher than in nonthrombosed veins in either the contralateral extremity of patients with DVT [SUVmax, 1.09 (0.25), P = 0.007] or control subjects [1.21 (0.22), P < 0.001]. The area under the receiver operating characteristic curve for SUVmax was 0.9773 (P < 0.001), indicating excellent accuracy. An SUVmax threshold of greater than 1.645 was 87.5% sensitive and 100% specific for DVT. Metabolic activity in thrombosed veins correlated significantly with time from DVT symptom onset (decrease in SUVmax of 0.02/d, P < 0.05). Best-fit-line analyses suggested that approximately 84 to 91 days after acute DVT, the maximum metabolic activity of thrombosed veins would return to normal levels.

Conclusions: F-FDG PET/CT is accurate for detecting acute symptomatic, proximal DVT. Metabolic activity in thrombosed veins decreases with time, suggesting that F-FDG PET may be helpful in assessing the age of the clot.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3564643PMC
http://dx.doi.org/10.1097/RLU.0b013e3182638934DOI Listing

Publication Analysis

Top Keywords

metabolic activity
24
activity thrombosed
20
thrombosed veins
16
f-fdg pet
12
f-fdg pet/ct
12
dvt metabolic
12
dvt
10
deep vein
8
vein thrombosis
8
control subjects
8

Similar Publications

A patent review of xanthine oxidase inhibitors (2021-present).

Expert Opin Ther Pat

December 2024

Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, China.

Introduction: Xanthine oxidase (XO) catalyzes the oxidation of both hypoxanthine and xanthine in the last two steps of the purine metabolic pathway, serving as a rate-limiting enzyme for uric acid production as well as a key target for the treatment of gout and other hyperuricemia-related conditions.

Areas Covered: This paper reviews XO inhibitors in patents from 2021 to the present. We summarize in detail the structural classes and characteristics, in vitro and in vivo biological results, and structure‒activity relationships of synthetic inhibitors, as well as the sources, specific structures, research methods, and biological activities of XO inhibitors from natural products.

View Article and Find Full Text PDF

(1) Background and aim: Aloe arborescens Mill. (A. arborescens) is one of the most widely distributed species in the genus Aloe and has garnered widespread recognition for its anticancer properties.

View Article and Find Full Text PDF

At the present stage, great progress has been achieved in understanding the mechanisms of the development of cerebral ischemia. This became possible due to the achievements of theoretical disciplines, in connection with which the general biological approach was formed in the study of pathogenesis of acute and chronic cerebrovascular disorders (CVD). The discovery of pathways of free radical oxidation in cerebral ischemia made it possible to substantiate and develop therapeutic strategies using drugs with antioxidant and neuroprotective activity.

View Article and Find Full Text PDF

Objective: To compare biomarkers of neurovascular unit (NVU) - S100β, NSE, BDNF and indicators of the brain electrical activity in patients who underwent coronary artery bypass grafting (CABG) depending on the use of different versions of multi-tasking cognitive training (CT).

Material And Methods: The study included 89 people, of whom 47 completed the CTI (postural and three cognitive tasks (counting backwards, verbal fluency and the open-ended task «Unusual use of an ordinary object») and 42 patients, who underwent CTII (visuomotor reaction and the same cognitive tasks) in the early postoperative CABG period. The patients of both groups underwent complex testing of psychomotor, executive functions, attention, short-term memory and EEG study in the perioperative period of CABG.

View Article and Find Full Text PDF

A and Extract Blend Attenuates Muscle Atrophy by Regulating Protein Metabolism and Antioxidant Activity.

J Med Food

December 2024

Division of Food and Nutrition and Human Ecology Research Institute, Chonnam National University, Gwangju, Republic of Korea.

Here, we investigated whether a mixture of and (1:3, KGC01CE) could suppress muscle atrophy in HO-induced C2C12 cells and dexamethasone-injected mice. Our results revealed that KGC01CE effectively safeguarded against HO-induced muscle atrophy in C2C12 cells compared with the same mixture at other ratios. We demonstrated that dexamethasone elicited oxidative stress in muscle tissue and decreased the grip strength and cross-sectional areas of muscle fibers; however, oral administration of KGC01CE (1:3) suppressed these dexamethasone-induced changes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!